Connor, Clark & Lunn Investment Management Ltd. Lexicon Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$1.0 - $1.53 $54,597 - $83,533	-54,597 Reduced 16.2%	282,467 $432,000
Q3 2023 Nov 13, 2023	BUY	$1.06 - $2.33 $2,981 - $6,554	2,813 Added 0.84%	337,064 $367,000
Q2 2023 Aug 10, 2023	BUY	$2.15 - $3.49 $270,723 - $439,453	125,918 Added 60.44%	334,251 $765,000
Q1 2023 May 09, 2023	BUY	$1.99 - $2.68 $146,814 - $197,719	73,776 Added 54.83%	208,333 $506,000
Q4 2022 Feb 10, 2023	BUY	$1.8 - $2.56 $242,202 - $344,465	134,557 New	134,557 $257,000
Q1 2021 May 13, 2021	SELL	$3.45 - $9.09 $166,459 - $438,583	-48,249 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$1.05 - $3.67 $65,114 - $227,591	-62,014 Reduced 56.24%	48,249 $165,000
Q3 2020 Nov 12, 2020	BUY	$1.44 - $2.1 $56,666 - $82,639	39,352 Added 55.49%	110,263 $159,000
Q2 2020 Aug 13, 2020	BUY	$1.75 - $2.3 $47,619 - $62,585	27,211 Added 62.27%	70,911 $141,000
Q1 2020 May 13, 2020	BUY	$1.8 - $4.28 $78,660 - $187,036	43,700 New	43,700 $85,000
Q1 2018 May 14, 2018	SELL	$7.86 - $11.39 $318,919 - $462,149	-40,575 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$8.77 - $12.28 $245,560 - $343,840	28,000 Added 222.66%	40,575 $401,000
Q3 2017 Nov 14, 2017	BUY	$12.17 - $16.3 $153,037 - $204,972	12,575	12,575 $155,000

Others Institutions Holding LXRX

# of Institutions

131

Shares Held

240M

Call Options Held

617K

Put Options Held

286K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $296M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account